Vortex Biosciences是一家致力于循环肿瘤细胞（CTC）液体检测的公司，从UCLA的微流体生物技术实验室孵化而来，由Dini Di Carlo博士和Elodie Sollier博士创立于2012年创立。
企业融资
2019年4月25日，Vortex Biosciences完成了A轮融资，该轮由EMV Capital投资。这笔资金主要用于整合下游业务。
产品服务
VTX-1液体活检系统提供一种自动化、无标记的用于从标准的8ml血液管中分离和纯化循环肿瘤细胞（CTC）的解决方案。VTX-1仪器通过微涡流快速处理样品获得高纯度的CTC（60%~70%的cell recovery）。VTX-1系统不需要进行样品预处理，只需将患者血液管加入一次管，装入并开始运行，自动分离约1-2小时，之后将CTC收集到ep管、培养皿、载玻片室或微孔条中。
相关阅读
http://www.prweb.com/releases/emv_capital_invests_in_leading_san_francisco_based_liquid_biopsy_company_vortex_biosciences_inc/prweb16264335.htm
M. Dhar et al., Nature Sci. Rep. (2018), 8(1):2592. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.
E. Kidess et al., Oncotarget (2016). DOI: 10.18632/oncotarget.13350. Enumeration and Targeted Analysis of KRAS, BRAF and PIK3CA Mutations in CTCs Captured by a Label-free Platform: Comparison to ctDNA and Tissue in Metastatic Colorectal Cancer.
H. Liu et al., Nature Genomic Medicine (2017), Nature Genomic Medicine, 2, 34. DOI: 10.1038/s41525-017-0034-3. Workflow optimization of whole genome amplification and targeted panel sequencing for CTC mutation detection.
C. Renier et al., Nature Precision Oncology (2017), 1, 15. DOI: 10.1038/s41698-017-0015-0. Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology.
J. Che et al., Lab Chip (2017), 17(8):1452-1461. DOI: 10.1039/C7LC00038C. Biophysical isolation and identification of circulating tumor cells.